358. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

DOI:

ラブゲリオ、ワクチンを接種している患者への追加の生命予後改善効果なし。症状の期間は短縮。

94％がSARS-CoV-2ワクチンを少なくとも3回接種している状況での調査。入院または死亡の複合アウトカムは、ラゲブリオ＋ルーチンケア群で1%，ルーチンケア群で1%で有意差なし。調整オッズ比 1.06; 0.81-1.41。

ワクチンの効果が高すぎて、ラゲブリオの追加はたいした足しにはならないということらしい。